Why Is Ohtuvayre So Hard to Find? [Explained for 2026]

If your doctor just prescribed Ohtuvayre (ensifentrine) for your COPD and you're struggling to fill it, you're not alone. Unlike most prescription medications you can pick up at your local CVS or Walgreens, Ohtuvayre comes with a set of access hurdles that catch many patients off guard. In this article, we break down exactly why Ohtuvayre is so difficult to find and what steps you can take to get it faster.

What Is Ohtuvayre and Why Was It Such a Big Deal?

Ohtuvayre (ensifentrine) received FDA approval on June 26, 2024, making it the first inhaled COPD maintenance therapy with a truly novel mechanism of action in over 20 years. Made by Verona Pharma, it's a first-in-class dual inhibitor of the enzymes phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). In plain terms: it simultaneously relaxes the muscles around your airways (bronchodilation) and reduces lung inflammation — without steroids — in a single inhaled treatment.

That novelty is exciting for COPD patients who haven't gotten enough relief from standard inhalers. But it also means Ohtuvayre faces all the access challenges that come with being a brand-new, first-of-its-kind specialty medication.

Reason #1: Ohtuvayre Is Only Available Through Specialty Pharmacies

This is the biggest reason most patients can't simply walk into a pharmacy and pick up Ohtuvayre. Verona Pharma distributes Ohtuvayre exclusively through a network of accredited specialty pharmacies. You cannot get it at a typical retail pharmacy like Walgreens, CVS, or Rite Aid.

Specialty pharmacies are equipped to handle complex medications that require special handling, storage, patient support, and insurance coordination. But this exclusivity means the prescription pathway is longer and more complicated than what most COPD patients are used to. Your doctor's office typically needs to enroll you in Verona's support program (Verona Pathway Plus) and send your prescription directly to a participating specialty pharmacy.

Reason #2: Most Insurance Plans Require Prior Authorization

Prior authorization (PA) is a process where your insurance company must approve a medication before they'll cover it. Virtually every major commercial insurer and Medicare plan requires prior authorization for Ohtuvayre. According to insurers like UnitedHealthcare, PA approval for Ohtuvayre requires:

A confirmed COPD diagnosis

Medical records showing FEV1/FVC ratio less than 0.7 (spirometry test result)

Post-bronchodilator FEV1 of 30% or greater (documenting disease severity)

This documentation process typically takes 2 to 4 weeks. During that time, you may be waiting without your medication. If the PA is denied, your doctor must file an appeal, which adds more time. Many patients go weeks — or even months — before finally receiving their first dose.

Reason #3: The Price Tag Creates Serious Access Barriers

Ohtuvayre has a list price of approximately $2,950 per month — or about $35,400 per year. That places it well above what most patients can afford out of pocket, and above most cost-effectiveness thresholds analyzed by the Institute for Clinical and Economic Review (ICER), which issued an access and affordability alert for the drug.

Because of that high price, many insurance plans are still working out where Ohtuvayre fits on their formularies — and some plans may not cover it at all or may place it on a high-cost specialty tier. When a drug isn't on formulary, the insurer won't pay for it, leaving patients to pay the full price or go without.

Reason #4: Formulary Uncertainty Across Insurance Plans

Ohtuvayre is a very new drug, having only been on the market since mid-2024. Insurance formularies — the lists of covered drugs — update at different times and at different speeds. Many plans hadn't finalized their coverage policies for Ohtuvayre through 2024, and some smaller or regional plans may still be catching up in 2025 and 2026.

This formulary uncertainty means that even if your doctor believes Ohtuvayre is the right choice for you, your plan may not agree — or may require you to try other COPD medications first (called step therapy) before approving a newer, more expensive drug.

Is There an Actual Shortage of Ohtuvayre?

As of 2026, the FDA has not declared an official shortage of Ohtuvayre. Unlike some other COPD and respiratory drugs that have been physically unavailable, Ohtuvayre's access challenges are primarily driven by insurance and distribution restrictions — not a lack of supply. Verona Pharma manufactures the drug and distributes it through their specialty pharmacy network.

That said, "hard to find" means different things to different patients. If your insurance won't cover it, your doctor hasn't enrolled in the support program, or you're dealing with a PA denial, Ohtuvayre might as well be unavailable. The access gap is real, even without a formal shortage designation.

What Can You Do If You Can't Get Ohtuvayre?

Here are steps that can help you navigate the access barriers:

Enroll in Verona Pathway Plus. This is Verona Pharma's patient support program. Call 1-833-372-8492 or ask your doctor's office to enroll you. They can help with specialty pharmacy coordination, insurance prior authorization, and financial assistance.

Ask your doctor to submit the PA right away. The sooner your doctor's office starts the prior authorization process, the sooner coverage decisions get made. Make sure they send the required spirometry results and chart notes.

Apply for the copay card. Patients with commercial insurance may pay as little as $0 per month with Verona Pathway Plus's copay program. This doesn't help Medicare patients, but it can dramatically reduce costs for those with employer or marketplace plans.

Appeal a denial. If your PA is denied, don't give up. Your doctor can submit a letter of medical necessity. Many PA denials are overturned on appeal, especially when clinical data from the ENHANCE trials is included.

Consider alternatives in the meantime. If you can't access Ohtuvayre while waiting for approval, talk to your doctor about COPD medications like tiotropium (Spiriva Respimat), Trelegy Ellipta, or Breztri Aerosphere as bridge options. Read our guide to Ohtuvayre alternatives for more information.

How medfinder Can Help

Once you have your prescription and insurance sorted out, finding which specialty pharmacy actually has your Ohtuvayre ready to dispense can still take coordination. medfinder is a service that calls pharmacies on your behalf to check availability and find which ones can fill your prescription. Instead of spending hours on hold, medfinder does the calling and texts you the results. For a specialty drug like Ohtuvayre, knowing exactly which pharmacy in your network can fill your prescription quickly can save you days of waiting.

For a step-by-step guide on locating Ohtuvayre, see our article on how to find Ohtuvayre in stock near you.

The Bottom Line

Ohtuvayre is a groundbreaking COPD medication, but its novelty and high price come with real-world access challenges in 2026. Being distributed exclusively through specialty pharmacies, requiring prior authorization from most insurers, and carrying a $2,950 monthly list price all create barriers that can leave patients waiting weeks or months. The good news: with the right steps — enrolling in Verona Pathway Plus, working with your doctor on PA paperwork, and applying for financial assistance — most patients with commercial insurance can get Ohtuvayre at little to no cost. The process just takes time and persistence.